ATA Mg® administration improves long-term synaptic plasticity and increases NMDA receptor subunit NR2B expression in two rodent pathological models. A-B. Adult rats submitted to low-magnesium diet. C-D. Adult APP/PS1 mice. A and C. In rats submitted to low-Mg Diet (A), the increase in fEPSP slope was significantly higher in ATA Mg® treated group (n = 6, 50 mg/kg bw/day ATA Mg®) compared to non-treated rats (n = 6) (Two-way Anova for Repeated measures, from T = 160 to T = 240 minutes, Holm-Sidak post hoc test, p < 0.05). In APP/PS1 mice (C), the increase in fEPSP slope was significantly higher in ATA Mg® treated group (n = 5, 700 mg/kg bw/day ATAMg®) compared to non-treated mice (n = 5) (Two-way Anova for Repeated measures, from T = 16 to T = 140 minutes, Holm-Sidak Post hoc test, p < 0.05). B and D. Different subunits of synaptic receptors were analyzed by western blotting. Loading was controlled by actin immunolabelling. The intensity of the signal obtained in ATA Mg® treated animals (n = 6 rats and n = 5 mice) was normalized against the intensity of the signal of non-treated animals (n = 6 rats and n = 6 mice). The increase in the expression of NR2B was significant in mice (t-test, p = 0.017) but not in rats (t-test, p =0.12).